(Q39376844)

11 September 2017

Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer (English)

1 reference

11 September 2017

1 reference

Satoru Takahashi

1

1 reference

11 September 2017

Hiroji Uemura

2

1 reference

11 September 2017

Azman Seeni

3

1 reference

11 September 2017

Mingxi Tang

4

1 reference

11 September 2017

Masami Komiya

5

1 reference

11 September 2017

Ne Long

6

1 reference

11 September 2017

Hitoshi Ishiguro

7

1 reference

11 September 2017

Yoshinobu Kubota

8

1 reference

11 September 2017

Tomoyuki Shirai

9

1 reference

11 September 2017

16 March 2012

1 reference

11 September 2017

1 reference

11 September 2017

72

1 reference

11 September 2017

1559-1572

1 reference

11 September 2017

14

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

11 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Cancer epidemiology in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

The endocrinology and developmental biology of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Endocrine treatment in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

The renin-angiotensin system and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Cancer, inflammation and the AT1 and AT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Renin-angiotensin system is an important factor in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Cancer burden in the year 2000. The global picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Prostate cancer chemoprevention: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Unconventional therapy for prostate cancer: good, bad or questionable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

A role for estrogen receptor beta in the regulation of growth of the ventral prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERbeta signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Castration-resistant prostate cancer: locking up the molecular escape routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

From pathogenesis to prevention of castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Targeting the androgen receptor pathway in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Interspecies scaling and comparisons in drug development and toxicokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Interspecific Scaling of Toxicity Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Chemoprevention of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22505

21 January 2018

Identifiers

DOI

10.1002/PROS.22505

1 reference

11 September 2017

1 reference